Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines

FMS-like tyrosine kinase 3 (FLT3) mutant acute myeloid leukemia (AML) occurs in approximately 30% of all AML patients and still has a poor prognosis. This study is directed to investigate gilteritinib in combination with homoharringtonine (HHT) on FLT3-ITD-mutant AML cell lines. In our study, we fou...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Jiayi, Huang, Honghui, Hu, Xiaoli, Lang, Wenjing, Fu, Wanbin, Xu, Lan, Qiu, Zilong, Zhong, Hua, Chen, Fangyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478557/
https://www.ncbi.nlm.nih.gov/pubmed/34594375
http://dx.doi.org/10.1155/2021/3766428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478557/
https://www.ncbi.nlm.nih.gov/pubmed/34594375
http://dx.doi.org/10.1155/2021/3766428

Ejemplares similares